Kaisi Kaidi Pharmaceutical Technology
Innovative drugs targeting nuclear receptors and GPCRs for metabolic diseases, tumors, and inflammation
About Kaisi Kaidi Pharmaceutical Technology
Cascade, established in December 2017, is a Sino-foreign joint venture biomedical enterprise specializing in the development of innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs). The company's core research and development (R&D) team is led by internationally renowned structural biologists and top nuclear receptor scientists, boasting over 20 years of experience in innovative drug research. Cascade focuses on addressing critical health issues such as metabolic diseases, tumors, and inflammation through structure-based drug design. The company operates in the biomedical sector, primarily serving healthcare providers, pharmaceutical companies, and research institutions. Cascade's business model revolves around the discovery, development, and commercialization of novel therapeutic drugs. Revenue is generated through partnerships, licensing agreements, and direct sales of their proprietary drugs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2026 | $44M | $175M | Taiping Healthcare Fund | ↗ |
| SERIES BOther financing | Nov 2025 | $41M | $165M | Zhangjiang Hi-Tech Park · River Head Capital · Fuho Capital · Lingang Blue Bay Fund | ↗ |
Growth signals
Latest recorded traffic for Kaisi Kaidi Pharmaceutical Technology is 90 monthly website visits, down 75% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kaisi Kaidi Pharmaceutical Technology in its local ecosystem
The Kaisi Kaidi Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
- PCPuhua Capital
NNFE Fund Management
CAS Investment Management
Hyfinity Investments- LILongpan Investment
- SIShanghai State Investment
- ZPZhangjiang Hi-Tech Park
River Head Capital- FCFuho Capital
- LFLingang Blue Bay Fund
- SCShanghai Pudong Venture Capital
Series B and later1 investor entered at this stage
- TFTaiping Healthcare Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kaisi Kaidi Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kaisi Kaidi Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









